Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1641-1660 of 1,743 trials

Kidney Transplant: Mannitol vs. Normal Saline

We are studying whether mannitol can help improve kidney transplant outcomes by reducing delayed graft function and early rejections. This trial involves both kidney donors and recipients.

End-Stage Renal Disease>2 yearsMonitoring phase (IV)Standard MedicinesNephrologyUrology

Triple-Negative Breast Cancer: Dato-DXd Treatment

We are studying a new drug for patients with triple-negative breast cancer and brain metastases to see if it can help shrink tumors and improve survival. The trial also examines safety and quality of life for participants.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Protection: Cilastatin vs. Thiosulfate

We are comparing cilastatin and thiosulfate to see which better protects kidneys during surgery with chemotherapy for cancer patients. This study aims to reduce kidney damage after the procedure.

Acute Kidney Injury>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrologyOncology

Multiple Sclerosis: Ozanimod Treatment Study

We are investigating how ozanimod affects inflammation in the brain and spinal cord for individuals with Multiple Sclerosis. This study aims to understand its potential benefits and any side effects.

Relapsing Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis

We are studying a new treatment using neural stem cells for people with ALS. The trial aims to assess safety and whether it may help slow disease progression.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Chronic Lymphocytic Leukemia: BGB-16673 Treatment Study

We are studying a new treatment called BGB-16673 for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously used other therapies. The goal is to see if it works better than current treatment options.

Chronic Lymphocytic Leukemia and Small Cell Lymphocytic Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

BCG Vaccine for Radiologically Isolated Syndrome (RIS)

We are studying whether the BCG vaccine can help reduce new brain lesions in people diagnosed with Radiologically Isolated Syndrome. The trial also looks at the safety of the vaccine and other brain changes over time.

Radiologically Isolated Syndrome>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

Ulcerative Colitis and Crohn’s Disease: Long-term Study of Zasocitinib

We are investigating the long-term safety and effectiveness of oral zasocitinib in adults with moderately to severely active ulcerative colitis and Crohn’s disease. This study is for those who have responded to treatment in previous trials.

Ulcerative ColitisCrohn's Disease>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

High Blood Pressure: Metyrapone for Adrenal Tumors

We are studying if adding Metyrapone helps patients with high blood pressure and adrenal tumors manage their condition better. This trial aims to improve blood pressure control in those with subclinical Cushing's syndrome.

Adrenal Incidentalomas and Mild Cushing’s Syndrome>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Colorectal Cancer: FOLFIRI and Cetuximab Treatment

We are studying whether a combination of FOLFIRI and Cetuximab is effective for patients with advanced colorectal cancer who have specific genetic markers. This research aims to improve first-line treatment options for these patients.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncologyUrology

Advanced Solid Tumors: PM534 Treatment

We are testing a new drug called PM534 for patients with advanced solid tumors. The goal is to learn about its safety and how it may help in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Systemic Lupus Erythematosus: AZD5492 Study

We are investigating a new medication for adults with systemic lupus erythematosus or idiopathic inflammatory myopathies. The study focuses on its safety and how the body processes the drug.

Systemic Lupus ErythematosusIdiopathic Inflammatory Myopathy>2 yearsSafety phase (I)Rheumatology

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Basal Cell Carcinoma: Electrochemotherapy vs. Radiotherapy

We are comparing a new treatment called electrochemotherapy with standard radiotherapy for small basal cell carcinomas. The study will also assess side effects, appearance after treatment, and patient satisfaction.

Basal Cell Carcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

Neuroblastoma: Innovative Stem Cell Transplant and Immunotherapy

We are studying a new stem cell transplant method followed by immunotherapy for children with relapsed or resistant high-risk neuroblastoma. This trial aims to evaluate the safety and effectiveness of this approach in improving treatment outcomes.

Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Rheumatoid Arthritis: CLN-978 Treatment

We are testing a new treatment called CLN-978 for patients with rheumatoid arthritis who haven't found relief from existing medications. The goal is to see if it can help manage their symptoms better.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology